دورية أكاديمية
Therapeutic applications of CRISPR/Cas9 mediated targeted gene editing in acute lymphoblastic leukemia: current perspectives, future challenges, and clinical implications.
| العنوان: | Therapeutic applications of CRISPR/Cas9 mediated targeted gene editing in acute lymphoblastic leukemia: current perspectives, future challenges, and clinical implications. |
|---|---|
| المؤلفون: | Assis AJB; Laboratory of Molecular Pathology of Cancer, Faculty of Health Sciences and Medicine, University of Brasília, Brasília, Brazil., Santana BLO; Laboratory of Molecular Pathology of Cancer, Faculty of Health Sciences and Medicine, University of Brasília, Brasília, Brazil., Gualberto ACM; Laboratory of Molecular Pathology of Cancer, Faculty of Health Sciences and Medicine, University of Brasília, Brasília, Brazil., Pittella-Silva F; Laboratory of Molecular Pathology of Cancer, Faculty of Health Sciences and Medicine, University of Brasília, Brasília, Brazil. |
| المصدر: | Frontiers in pharmacology [Front Pharmacol] 2023 Dec 07; Vol. 14, pp. 1322937. Date of Electronic Publication: 2023 Dec 07 (Print Publication: 2023). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Media] |
| مستخلص: | Acute Lymphoblastic Leukemia (ALL) is the predominant hematological malignancy in pediatric populations, originating from B- or T-cell precursors within the bone marrow. The disease exhibits a high degree of heterogeneity, both at the molecular level and in terms of clinical presentation. A complex interplay between inherited and acquired genetic alterations contributes to disease pathogenesis, often resulting in the disruption of cellular functions integral to the leukemogenic process. The advent of CRISPR/Cas9 as a gene editing tool has revolutionized biological research, underscoring its potential to modify specific genomic loci implicated in cancer. Enhanced understanding of molecular alterations in ALL has facilitated significant advancements in therapeutic strategies. In this review, we scrutinize the application of CRISPR/Cas9 as a tool for identifying genetic targets to improve therapy, circumvent drug resistance, and facilitate CAR-T cell-based immunotherapy. Additionally, we discuss the challenges and future prospects of CRISPR/Cas9 applications in ALL. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Assis, Santana, Gualberto and Pittella-Silva.) |
| References: | Haematologica. 2020 Sep 10;105(11):2524-2539. (PMID: 33054110) Nat Biotechnol. 2022 Feb;40(2):189-193. (PMID: 33927418) Front Genet. 2023 Oct 16;14:1273994. (PMID: 37908590) N Engl J Med. 2021 Jan 21;384(3):252-260. (PMID: 33283989) Cells. 2020 Jan 15;9(1):. (PMID: 31952221) Blood Adv. 2019 Dec 23;3(24):4252-4263. (PMID: 31867596) Haematologica. 2020 May;105(5):e232-e236. (PMID: 31537693) Sci Transl Med. 2022 Oct 26;14(668):eabq3010. (PMID: 36288281) Science. 2012 Aug 17;337(6096):816-21. (PMID: 22745249) Nature. 2017 Feb 23;542(7642):479-483. (PMID: 28192788) Yonsei Med J. 2022 Feb;63(2):105-113. (PMID: 35083895) Blood Adv. 2021 Oct 12;5(19):3876-3890. (PMID: 34492683) Hum Mol Genet. 2014 Sep 15;23(R1):R40-6. (PMID: 24651067) Sci Rep. 2021 Jun 23;11(1):13158. (PMID: 34162911) Nature. 2016 Jan 28;529(7587):490-5. (PMID: 26735016) Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221132078. (PMID: 36254536) Clin Lab Med. 2021 Sep;41(3):405-416. (PMID: 34304772) J Natl Cancer Inst. 2022 Sep 9;114(9):1287-1295. (PMID: 35575404) Pediatr Clin North Am. 2015 Feb;62(1):47-60. (PMID: 25435111) Virchows Arch. 2023 Jan;482(1):11-26. (PMID: 36422706) Elife. 2020 Oct 01;9:. (PMID: 33001025) Cancer Med. 2018 Apr;7(4):1297-1316. (PMID: 29473342) Trends Biotechnol. 2023 Aug;41(8):1000-1012. (PMID: 37002157) J Gen Virol. 2015 Aug;96(8):2381-2393. (PMID: 25854553) Cancer Gene Ther. 2022 Aug;29(8-9):1080-1096. (PMID: 34987176) Nat Biotechnol. 2021 Feb;39(2):198-206. (PMID: 32958957) Sci Rep. 2021 Jan 12;11(1):769. (PMID: 33436855) Cancer Commun (Lond). 2020 Oct;40(10):501-517. (PMID: 32820611) Sci Adv. 2022 Dec 14;8(50):eadd6403. (PMID: 36516256) Cancer Res. 2020 Dec 1;80(23):5189-5202. (PMID: 33067268) N Engl J Med. 2021 Aug 5;385(6):493-502. (PMID: 34215024) Mol Ther. 2017 Aug 2;25(8):1782-1789. (PMID: 28527722) Cells. 2020 Jul 02;9(7):. (PMID: 32630835) Nat Cancer. 2021 Mar;2(3):284-299. (PMID: 34151288) Front Bioeng Biotechnol. 2023 Feb 16;11:1138596. (PMID: 36873375) Blood. 2021 Dec 9;138(23):2383-2395. (PMID: 34280258) Blood. 2022 Feb 3;139(5):748-760. (PMID: 34587248) Science. 2016 Jan 1;351(6268):84-8. (PMID: 26628643) Haematologica. 2019 May;104(5):881-893. (PMID: 30923099) Pharmaceutics. 2022 Jun 19;14(6):. (PMID: 35745875) Biochem Biophys Res Commun. 2022 Sep 17;621:74-79. (PMID: 35810594) Nature. 2022 Jan;601(7893):428-433. (PMID: 34937946) J Hematol Oncol. 2015 May 29;8:61. (PMID: 26022503) Mol Cancer. 2022 Mar 18;21(1):78. (PMID: 35303871) Nat Biotechnol. 2013 Sep;31(9):833-8. (PMID: 23907171) Lancet. 2020 Apr 4;395(10230):1146-1162. (PMID: 32247396) Nat Genet. 2022 Feb;54(2):170-179. (PMID: 35115686) Cell. 2013 Sep 12;154(6):1380-9. (PMID: 23992846) |
| فهرسة مساهمة: | Keywords: CRISPR/Cas9; acute lymphoblastic leukemia; current perspectives; gene editing; therapeutic strategies cancer treatment |
| تواريخ الأحداث: | Date Created: 20231222 Latest Revision: 20231223 |
| رمز التحديث: | 20231223 |
| مُعرف محوري في PubMed: | PMC10733529 |
| DOI: | 10.3389/fphar.2023.1322937 |
| PMID: | 38130408 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1663-9812 |
|---|---|
| DOI: | 10.3389/fphar.2023.1322937 |